Surgical Infections withEnterococcus: Outcome in Patients Treated with Ertapenem versus Piperacillin-Tazobactam
- 1 December 2002
- journal article
- clinical trial
- Published by Mary Ann Liebert Inc in Surgical Infections
- Vol. 3 (4) , 337-349
- https://doi.org/10.1089/109629602762539553
Abstract
Background: The pathogenicity of Enterococcus in polymicrobial surgical infections is controversial. The objective of this analysis was two-fold. The impact of Enterococcus on clinical outcome was assessed in adults with complicated intra-abdominal (IAI), complicated skin and skin structure (CSSSI), or acute pelvic (PI) infection treated with ertapenem or piperacillin-tazobactam, which is more active in vitro against enterococci than ertapenem. Baseline characteristics were identified that were associated with Enterococcus infection and with treatment failure. Methods: This analysis included 1,558 patients treated in three randomized, triple-blind studies. Of these patients, 223 had Enterococcus in initial cultures: 125 of 623 (20%) with IAI, 28 of 529 (5%) with CSSSI, and 70 of 406 (17%) with PI. Logistic regression models were fit to assess each objective. Results: The cure rates for the two treatment groups were similar in each of the three studies, regardless of the presence or absence of Enterococcus. Cure rates for both treatment groups combined were significantly lower in patients with Enterococcus than without Enterococcus for IAI (76% [69/91] versus 87% [264/305], OR 2.3 [95% CI, 1.2–4.1], P = 0.009) and CSSSI (58% [11/19] versus 84% [241/287], OR 3.8 [95% CI, 1.5–10.0], P = 0.010); but for PI, rates were similar (96% [50/52] versus 92% [188/205], OR 0.4 [95% CI, 0.1–1.9], P = 0.220). Characteristics predictive of the presence of Enterococcus were Pseudomonas aeruginosa as a baseline pathogen for IAI, older age, and the presence of a complicating underlying disease for CSSSI, and infection severity rated moderate rather than severe for PI. The strongest predictors of treatment failure were >2 days postoperative infection at study entry for patients with IAI and older age for patients with CSSSI. Conclusion: Choice of antimicrobial therapy did not affect cure rates in patients with or without Enterococcus. The strongest predictors of failure were postoperative infection at study entry in patients with IAI and older age in patients with CSSSI.Keywords
This publication has 18 references indexed in Scilit:
- Clinafloxacin versus Piperacillin-Tazobactam in Treatment of Patients with Severe Skin and Soft Tissue InfectionsAntimicrobial Agents and Chemotherapy, 2001
- Coverage of Enterococci in Community Acquired Secondary Peritonitis: Results of a Randomized TrialSurgical Infections, 2000
- Editorial:Enterococcusin PerspectiveSurgical Infections, 2000
- Definition of the role of enterococcus in intraabdominal infection: Analysis of a prospective randomized trialSurgery, 1995
- Treatment of hospitalized patients with complicated skin and skin structure infections: double-blind, randomized, multicenter study of piperacillin-tazobactam versus ticarcillin-clavulanate. The Piperacillin/Tazobactam Skin and Skin Structure Study GroupAntimicrobial Agents and Chemotherapy, 1993
- General Guidelines for the Clinical Evaluation of Anti-Infective Drug ProductsClinical Infectious Diseases, 1992
- Enterococcal Infections in Surgical Patients: The Mystery ContinuesClinical Infectious Diseases, 1992
- Pathogenicity of the Enterococcus in Surgical InfectionsAnnals of Surgery, 1990
- Role of enterococcus in intraabdominal sepsisThe American Journal of Surgery, 1984
- Enterococcal Bacteremia Clinical Implications and Determinants of DeathAnnals of Surgery, 1982